LexDanaLexDanabeta
Inventor

Rene Bernards

Inventor
Amsterdam, NL

Overview

17→
Patents
1999–2020
Patent span
Human necessities
Primary field (CPC A)

Patents· 17 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary
A61KPreparations for medical, dental or toiletry purposes19%
C07KPeptides17%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations15%
G01NInvestigating or analysing materials by determining their chemical or physical properties13%
C12NMicroorganisms or enzymes8%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms8%
G16BBioinformatics, i.e. information and communication technology [ict] specially adapted for genetic or protein-related data processing in computational molecular biology6%
G16ZInformation and communication technology [ict] specially adapted for specific application fields, not otherwise provided for6%
Y02ATechnologies for adaptation to climate change6%
G06FElectric digital data processing2%
PatentTitleYear
10,864,179Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma202010,398,696Combinations for treatment of cancer20199,909,185'Diagnosis and prognosis of breast cancer patients'20188,969,544'Combined use of PRAME inhibitors and HDAC inhibitors'20157,928,081'Combined use of PRAME inhibitors and HDAC inhibitors'20117,863,001'Diagnosis and prognosis of breast cancer patients'20117,514,209'Diagnosis and prognosis of breast cancer patients'20097,171,311'Methods of assigning treatment to breast cancer patients'20077,012,128'Interaction between cyclin D1 and steroid receptor co-activators and uses thereof in assays'20066,699,475'Recombinant pox virus for immunization against tumor-associated antigens'20046,448,376'Transcription factor-E2F-5'20026,368,809'E2F ubiquitination domain, and assays for inhibitors and enhancers of E2F ubiquitination'20026,350,572'Interaction between cyclin D1 and steroid receptor coactivators and users thereof in assays'20026,303,335'Transcription factor E2F-4'20016,045,999'Transcription factor E2F-4'20006,033,843'Interaction of cyclin D1 and estrogen receptor and its use in assays'20005,985,283'Adenovirus E1A-Associated protein BS69, inhibitor of E1A-transactivation'1999

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1999–2002Patents assigned to PROLIFIX LTD (7)· patent assignee history
1999–2020Based in Amsterdam, NL· patent location history
2000–2006Based in Alconde, NL· patent location history
2002Based in Alcoude, NL· patent location history
2004Based in Brookline, MA, US· patent location history
2007–2011Patents assigned to NETHERLANDS CANCER INST (3)· patent assignee history
2007–2018Based in Abcoude, NL· patent location history
2011–2015Patents assigned to EPPING MIRJAM (2)· patent assignee history
2011–2018Patents assigned to MERCK SHARP & DOHME (2)· patent assignee history
2019–2020Patents assigned to STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS (2)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
PROLIFIX LTD71999–2002
NETHERLANDS CANCER INST32007–2011
EPPING MIRJAM22011–2015
MERCK SHARP & DOHME22011–2018
STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS22019–2020
Locations
LocationPatentsSpan
Amsterdam, NL91999–2020
Abcoude, NL42007–2018
Alconde, NL22000–2006
Brookline, Massachusetts, US12004
Alcoude, NL12002